

DEAR BARON GLOBAL ADVANTAGE FUND SHAREHOLDER:

PERFORMANCE

We had a great start to the year.

Baron Global Advantage Fund (the "Fund") gained 26.2% (Institutional Shares) in the first quarter, significantly outpacing the gains of 12.2% and 14.5% for the Fund's benchmarks, MSCI ACWI and MSCI ACWI Growth Indexes, respectively.

Table I.
Performance[†]
Annualized for periods ended March 31, 2019

	Baron Global Advantage Fund Retail Shares ^{1,2}	Baron Global Advantage Fund Institutional Shares ^{1,2}	MSCI ACWI Index ¹	MSCI ACWI Growth Index ¹
Three Months ³	26.10%	26.17%	12.18%	14.48%
One Year	13.47%	13.73%	2.60%	4.47%
Three Years	23.55%	23.81%	10.67%	12.30%
Five Years	12.88%	13.09%	6.45%	8.52%
Since Inception (April 30, 2012)	14.17%	14.41%	8.71%	9.95%

After experiencing broad-based declines at the end of last year, the global equity markets reversed course, in our opinion, largely due to the Federal Reserve's decision to put further tightening on an indefinite hold. With rates remaining squarely in an "accommodative" range, the investing public was free again to focus on the longer-term company specific fundamentals, with growth investors once again focusing on finding big ideas. This is an environment that we tend to do well in.

The excellent start to the year can be attributed largely to strong stock selection, although overweights in China and Argentina, and underweights in Japan and Europe also contributed positively to relative returns. For the first time ever, we had 10 investments contribute at least 100 basis points each in a single quarter—**Veeva, Alibaba, EPAM, argenx, Sage, Constellation Software, Worldpay, PagSeguro, Guardant Health, and MercadoLibre**. There were an additional 14 investments that contributed at least 50 basis points each, and 15 more that contributed at least 10 basis points each.

Performance listed in the table above is net of annual operating expenses. Annual expense ratio for the Retail Shares and Institutional Shares as of December 31, 2018 was 1.45% and 1.18%, respectively, but the net annual expense ratio is 1.15% and 0.90% (net of the Adviser's fee waivers), respectively. The performance data quoted represents past performance. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate; an investor's shares, when redeemed, may be worth more or less than their original cost. The Adviser reimburses certain Baron Fund expenses pursuant to a contract with an 11-year term and the Fund's transfer agency expenses may be reduced by expense offsets from an unaffiliated transfer agent, without which performance would have been lower. Current performance may be lower or higher than the performance data quoted. For performance information current to the most recent month end, visit www.BaronFunds.com or call 1-800-99BARON.

[†] The Fund's historical performance was impacted by gains from IPOs and/or secondary offerings. There is no guarantee that these results can be repeated or that the Fund's level of participation in IPOs and secondary offerings will be the same in the future.

¹ The indexes are unmanaged. The MSCI ACWI indexes cited are unmanaged, free float-adjusted market capitalization weighted indexes reflected in US dollars. The MSCI ACWI Growth Index Net USD measures the equity market performance of large- and mid-cap growth securities across developed and emerging markets. The MSCI ACWI Index Net USD measures the equity market performance of large- and mid-cap securities across developed and emerging markets. The indexes and the Baron Global Advantage Fund include reinvestment of dividends, net of foreign withholding taxes, which positively impact the performance results.

² The performance data in the table does not reflect the deduction of taxes that a shareholder would pay on Fund distributions or redemption of Fund shares.

³ Not annualized.

* The Lipper Fund Awards, granted annually, highlight funds and fund companies that have excelled in delivering consistently strong risk-adjusted performance relative to their peers.

The Lipper Fund Awards are based on the Lipper Leader for Consistent Return rating, which is a risk-adjusted performance measure calculated over 36, 60 and 120 months. The fund with the highest Lipper Leader for Consistent Return (Effective Return) value in each eligible classification wins the Lipper Fund Award. For more information, see lipperfundawards.com. Although Lipper makes reasonable efforts to ensure the accuracy and reliability of the data contained herein, the accuracy is not guaranteed by Lipper.

** Morningstar calculates the Morningstar US Fund World Large Stock Category average using the Morningstar Fractional Weighting methodology. Morningstar rankings are based on total returns and do not include sales charges. Total returns do account for management, administrative, and 12b-1 fees and other costs automatically deducted from fund assets. As of 3/31/2019, the Category consisted of 900, 732, 617, and 505 share classes for the 1-, 3-, 5-year, and since inception (4/30/2012) periods. Morningstar ranked **Baron Global Advantage Fund Institutional** Share Class in the 2nd, 1st, 1st, and 1st percentiles, respectively.

***As of 3/31/2019, the annualized returns of the Morningstar US Fund World Large Stock Category average were 1.85%, 9.96%, 5.89%, and 8.47% for the 1-, 3-, 5-year, and since inception (4/30/2012) periods.



ALEX UMANSKY

PORTFOLIO MANAGER

Retail Shares: BGAFX
Institutional Shares: BGAIX
R6 Shares: BGLUX

We are happy to report that in March 2019, Baron Global Advantage Fund was named the best fund in its category by Lipper Analytics for risk-adjusted returns over the last three years.*

According to Morningstar, for the period ended March 31, 2019, Baron Global Advantage Fund is ranked in the top 1% for the 3-year, 5-year and since inception returns; and top 2% for the one-year period. The Fund has been awarded a 5-star Morningstar rating for its 3-year, 5-year, and overall risk-adjusted performance.**

Since its inception on April 30, 2012, the Baron Global Advantage Fund has returned 153.8% (Institutional Shares) cumulatively, compared to 78.2% for the MSCI ACWI Index and 92.8% for the MSCI ACWI Growth Index, the Fund's benchmarks. Over that same period of time, the Fund has outperformed the Morningstar US Fund World Large Stock Category average by 78.4%, cumulatively.***

Over the last five years, the Fund has outperformed the MSCI ACWI Index by 6.6% per year, the MSCI ACWI Growth Index by 4.6% per year, and its Morningstar US Fund World Large Stock Category average by 7.2% per year.



Baron Global Advantage Fund

We continue to believe that relative performance results are most informative when measured on a rolling basis over longer periods of time. On a monthly basis, the Baron Global Advantage Fund has outperformed its benchmarks on average, 65% of the time since its inception on April 30, 2012. On a rolling 3-month basis, we improve to 66%. Rolling 12-month results show a success rate of 74%, and rolling 36-month results improve it further to 88%. When measured over 5-year rolling periods, the Fund has outperformed both of its benchmarks 100% of the time.

Table II.
Percentage of time Fund outperformed benchmarks over different time periods from inception through March 31, 2019

Rolling Return Period	1 Month	3 Months	1 Year	3 Years	5 Years
Fund Outperformance vs. MSCI ACWI Index	66%	67%	76%	92%	100%
Fund Outperformance vs. MSCI ACWI Growth Index	63%	64%	71%	83%	100%

Unless otherwise noted, all performance and performance-related calculations are based on the Institutional Shares. Calculation is based on monthly returns.

Table III.
Top contributors to performance for the quarter ended March 31, 2019

	Quarter End Market Cap (billions)	Percent Impact
Veeva Systems Inc.	\$ 18.6	1.60%
Alibaba Group Holding Limited	471.7	1.58
EPAM Systems, Inc.	9.2	1.55
argenx SE	4.7	1.49
Sage Therapeutics, Inc.	8.1	1.31

Veeva Systems Inc. is the leading provider of cloud-based solutions targeted at the life sciences industry, offering customer relationship management, content, collaboration, and data management solutions. Shares of Veeva were up 42% in the first quarter with the company's results continuing to outperform expectations. Veeva's innovative culture and significant market share in Life Sciences CRM continue to drive growth in its more mature commercial business. Veeva continued growing wallet share with existing customers via cross-sales of add-on products while continuing to gain market share in Server Message Block. We believe the value proposition of recently announced products such as Nitro is attractive to customers as they are looking to digitally transform and take advantage of data analytics. Moreover, Vault continued growing rapidly at scale, is now almost 50% of the business, and grew approximately 45% year-over-year in the most recent quarter. We expect that with the growing adoption of Vault products, Veeva will become even more strategic for customers, presenting significant long-term growth opportunities for the company. The ongoing evolution of the Veeva platform, its ability to deliver significant value to its

customers, and the company's impressive growth and margin profile make Veeva a unique long-term investment opportunity in our opinion.

Alibaba Group Holding Limited is the largest retailer and e-commerce company in China, operating the shopping platforms Taobao and Tmall. Alibaba also holds 33% of Ant Financial, whose brand, Alipay, is the largest third-party online payment provider in China. Shares of Alibaba were up 33% during the first quarter, more than offsetting their decline in the fourth quarter of 2018 as the company continued showing robust growth at scale (Alibaba's core commerce revenues were up 40% year-over-year to over Rmb 100 billion) while continuing to invest in additional areas, such as cloud computing, grocery, logistics, and food delivery, expanding the Alibaba platform. We remain optimistic about Alibaba's long-term opportunity as the company continues to benefit from e-commerce penetration (still only about 20% of total retail) while utilizing its platform (700 million monthly active users) to expand into additional areas.

EPAM Systems, Inc. provides outsourced software development to business customers using highly-skilled, low-cost employees in Eastern Europe and Russia. Shares of EPAM were up 46% during the first quarter after the company reported quarterly results that exceeded investor expectations. Revenue growth accelerated to 26% on an organic, constant-currency basis, and the operating margin expanded meaningfully. Customer demand remains strong for the company's software development, as customers around the world are looking to digitally transform their businesses in order to remain competitive and fend off quicker, nimbler start-ups. We continue to own the stock due to EPAM's long runway for growth, superb execution, and differentiated and highly-technical workforce, which enables EPAM to have better pricing power than peers.

argenx SE is a clinical-stage biotechnology company focused on research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. argenx stock was up 30% during the first quarter after the company disclosed a milestone payment was received from AbbVie for commencing clinical development in ABBV-151 to treat locally advanced or metastatic solid tumors. Moreover, argenx announced an exclusive licensing deal to utilize Halozyme's subcutaneous technology enhancing its lead in the FcRn market. We believe that argenx's antibody FcRn platform is one of the most valuable assets in the biotechnology development space, offering significant long-term potential as the company proves its products' effectiveness in multiple autoantibody disorders.

Sage Therapeutics, Inc. is focused on developing novel drugs for central nervous system disorders. Shares of Sage were up 66% in the quarter as the company announced several positive developments for its lead assets SAGE-547/SAGE-217 in postpartum depression and major depressive disorder. Most notably, Sage delivered a best-case scenario outcome for the SAGE-217 trial in MDD (Major Depressive Disorder) in January, and this was followed by an approval in March of Zulresso for postpartum depression. We expect Sage shares to continue performing well as its pipeline matures and the company executes on its commercial opportunities.

Table IV.

Top detractors from performance for the quarter ended March 31, 2019

	Quarter End Market Cap or Market Cap When Sold (billions)	Percent Impact
Take-Two Interactive Software, Inc.	\$10.7	−0.25%
Tesla, Inc.	48.3	−0.20
Bolsas y Mercados Argentinos S.A.	0.6	−0.18
AxoGen, Inc.	0.8	−0.04
Housing Development Finance Corporation Limited	48.9	−0.04

Shares of **Take-Two Interactive Software, Inc.**, a video game publisher, were down 8% during the first quarter, detracting from performance despite solid earnings and optimistic commentary about future growth prospects. The stock traded down because of negative sentiment surrounding the video game industry due to heightened competition, 2019 guidance that fell short of investor expectations, and questions regarding the potential of Red Dead Redemption Online. We retain conviction as we believe Take-Two has an excellent management team, continues to benefit from the shift to digital, and has great IP (most notably *Grand Theft Auto*, *Red Dead Redemption*, *NBA 2K*, and *Borderlands*) that continues to perform well.

Tesla, Inc. designs, manufactures, and sells fully electric vehicles, solar products, and energy storage solutions. Following strong execution during the second half of 2018, 2019 started with a complicated quarter with slower deliveries than expected. During the quarter, Tesla noted delays in international deliveries, headcount reduction, and potential changes to its go-to-market approach by closing some of its retail stores. These announcements increased short-term uncertainty pressuring the stock down 16%. We remain focused on the long-term opportunity as Tesla ramps up manufacturing, supply chain, and delivery rapidly to sell significantly more cars over the next few years. We believe the Model 3 program is nearing a tipping point with the availability of sub-\$40,000 options, presenting a strong mass-market opportunity. Moreover, Tesla's expansion into China and the introduction of Model Y over the next few years should help the company expand its addressable market while entering the growing SUV segment. We believe electric vehicles have distinct advantages over combustion-engine vehicles, and with rapidly approaching price parity, we believe they will capture significant market share with Tesla remaining a leading player in this market transition.

Bolsas y Mercados Argentinos S.A. is Argentina's only vertically integrated stock exchange and sole custodian for securities. Shares of Bolsas declined 25% during the quarter after the company reported weaker-than-expected fourth quarter of 2018 results, mostly driven by lower non-operating financial income and, to a lesser extent, weaker trading volumes in equities and assets under custody. Macro headlines continue to dominate short-term trading in Argentinian equities. With January inflation reported above expectations, the negative cycle of currency depreciation, rising rates and slower expected growth rates resumed. The weaker macro environment could also be a headwind for the incumbent president at the upcoming elections in October. If incumbent Cambiemos is not re-elected, investors' concern about the current reform-driven agenda, fiscal responsibility, and orthodox economic policies may be heightened. Notwithstanding near-term concerns, we believe that Bolsas has significant growth potential ahead, driven by the development of local capital markets, which should drive increasing penetration and additional revenue opportunities.

AxoGen, Inc. sells products for nerve repair, including Avance Nerve Graft. Shares detracted from the Fund's performance following the company's earnings announcement, reporting a shortfall in sales as well as reduced annual guidance due to a leadership change in the sales force and sales productivity challenges. We sold our position to pursue other higher-conviction investment ideas.

Housing Development Finance Corporation Limited ("HDFC") is India's largest and most reputable lender with mortgage origination, asset management, life insurance, and real estate businesses. While shares of HDFC were up 1% in the first quarter, they underperformed the Indian market by about 6%, as the company worked through a shock to short-term liquidity conditions that was triggered by a large default in the country. This had several impacts on HDFC's results, including lower loan growth, spread compression, and concerns about the quality of the real estate developer book. Some of these impacts are transitory and have begun to normalize, but lingering uncertainties impacted stock performance over the last quarter. We take comfort in HDFC's history of prudent risk management, and we continue to see an attractive long-term growth opportunity for the company due to rising demand for housing and policy support for the sector. HDFC's non-lending subsidiaries provide additional opportunity for value creation.

PORTFOLIO STRUCTURE

The portfolio is constructed on a bottom-up basis with the quality of ideas and conviction level having the most significant roles in determining the size of each individual investment. Sector or country weights tend to be an outcome of the portfolio construction process and are not meant to indicate a positive or a negative "view."

The top 10 positions represented 38.9% of the Fund, and the top 20 represented 63.1%. Our investments in the Information Technology, Consumer Discretionary, Health Care, Communication Services, and Financials sectors, as classified by GICS, represented 92.0% of the Fund's assets. Our investments in companies domiciled outside the U.S. represented 47.4% of assets.

Table V.

Top 10 holdings as of March 31, 2019

	Quarter End Market Cap (billions)	Quarter End Investment Value (millions)	Percent of Net Assets
Amazon.com, Inc.	\$874.7	\$7.9	5.3%
Alibaba Group Holding Limited	471.7	7.7	5.2
Alphabet Inc.	816.8	7.2	4.8
argenx SE	4.7	5.7	3.9
Illumina, Inc.	45.6	5.7	3.8
Naspers Limited	101.5	5.1	3.4
Veeva Systems Inc.	18.6	5.0	3.4
EPAM Systems, Inc.	9.2	4.6	3.1
Constellation Software, Inc.	18.0	4.5	3.0
Mellanox Technologies Ltd.	6.5	4.5	3.0

Baron Global Advantage Fund

EXPOSURE BY COUNTRY

Table VI.

Percentage of securities by country as of March 31, 2019

	Percent of Net Assets
United States	45.1%
China	12.2
India	6.5
Netherlands	6.2
Israel	5.3
Argentina	4.1
Brazil	4.0
South Africa	3.4
Canada	3.0
United Kingdom	1.6
Germany	0.9
Japan	0.2

RECENT ACTIVITY

During the quarter, we initiated 5 new investments and added to 26 existing positions as we put the Fund's inflows to work. We also sold out of 5 investments that were not able to graduate into "core" holdings. We exited the March quarter with 48 holdings, which include shares of **Mellanox Technologies Ltd.** and **Worldpay, Inc.** whose acquisitions are expected to close in the second half of the year.

Table VII.

Top net purchases for the quarter ended March 31, 2019

	Quarter End Market Cap (billions)	Amount Purchased (millions)
Illumina, Inc.	\$ 45.6	\$2.7
Amazon.com, Inc.	874.7	2.6
Alphabet Inc.	816.8	2.2
Accelaron Pharma Inc.	2.4	2.1
Alibaba Group Holding Limited	471.7	2.1

During the first quarter, we put the Fund's inflows to use by allocating new capital to 26 existing investments, which included four of our highest conviction ideas – **Illumina, Inc.**, **Amazon.com, Inc.**, **Alphabet Inc.** and **Alibaba Group Holding Limited**. We also initiated a new small position in **Accelaron Pharma Inc.**

Accelaron is a biotechnology company focused on the development of Luspatercept for anemias caused by myelodysplastic syndrome, beta thalassemia, and myelofibrosis. We think Luspatercept is likely to generate north of \$2 billion to \$3 billion in sales at peak, making the shares undervalued at an enterprise value of around \$2 billion. In addition to the inherent potential of Luspatercept, Accelaron is developing muscle and respiratory platforms that should increase its addressable market. We are taking advantage of the lack of news flow to build our position.

Table VIII.

Top net sales for the quarter ended March 31, 2019

	Market Cap When Sold (billions)	Amount Sold (millions)
Activision Blizzard, Inc.	\$36.1	\$3.0
Tenable Holdings, Inc.	2.5	1.2
Varonis Systems, Inc.	1.8	0.8
AxoGen, Inc.	0.8	0.6
AnaptysBio, Inc.	1.8	0.5

We eliminated **Activision Blizzard, Inc.** during the quarter as its shares continued to be under pressure following uncertainty regarding the launch slate of new releases for 2019 and as the company guided for EPS well below estimates. The surprising success of Electronic Arts' recent *Apex Legends* along with the continued popularity of *Fortnite* (resulting in a more "hit-driven" industry) and the slowing benefits from the transition to digital distribution also contributed to our decision.

We sold **Tenable Holdings, Inc.**, a Maryland-based cybersecurity company focused on the Vulnerability Management and Cyber Exposure markets. While the stock has done well since its IPO last July and reported solid quarterly results, we sold our shares in order to re-allocate capital to higher conviction ideas.

We also sold our position in **Varonis Systems, Inc.**, which provides a software platform that allows enterprises to map, analyze, manage, and migrate their unstructured data. The company specializes in human-generated unstructured data, including spreadsheets, documents, presentations, e-mails, and employee generated data. Our sale came after the company unexpectedly announced a transition in the business model causing a thesis change and our move to the sidelines.

Finally, we eliminated two smaller Health Care investments in **AxoGen, Inc.** and **AnaptysBio, Inc.** and re-allocated proceeds to higher conviction ideas.

OUTLOOK

After a difficult 2018, the first quarter of this year proved to be especially rewarding for global growth investors and many of our companies have performed exceedingly well, with the Fund's shares appreciating over 26% in a three-month period. With a strong absolute and relative performance run, it has undeniably been a favorable environment for the way in which we invest. Over the last 12 months, we have observed a noticeable uptick in volatility; however, we continue to do what we do, which is focus on big ideas and invest for the long term. By and large, we continue to see favorable fundamentals for most of our investments. Valuations, though no longer cheap, remain reasonable in our view, especially when compared to available alternatives. Moreover, the earnings outlook for 2019 remains optimistic. More relevant to our portfolio, e-commerce growth and spending on digital transformations are continuing to accelerate, with spending on cloud computing and big data growing over 60%, and even faster than that in Asia. The digitization phenomenon that we believe will dominate corporate spending for years to come is starting to reach inflection points in many new areas where not only media and retail, but health care, transportation, and consumer banking are in the midst of full-blown disruptions. We believe this should continue to favor many of the companies we invest in.

MARCH 31, 2019

Baron Global Advantage Fund

Every day we live and invest in a world full of uncertainty. Fed policy, potential trade wars, the health of EM economies, energy prices, global politics, terrorism—these are all serious challenges with clearly uncertain outcomes. History would suggest that most will prove passing or manageable. The business of capital allocation (or investing) is the business of taking risk, managing the uncertainty, and taking advantage of the long-term opportunities that those risks and uncertainties create. We believe that our process is the right one and that it will enable us to make good investment decisions over time.

Our goal remains to maximize long-term returns without taking significant risks of permanent loss of capital. We focus on identifying and investing in what we believe are unique companies with sustainable competitive

advantages that have the ability to compound capital at high rates of return for extended periods of time. We are optimistic about the long-term prospects of the companies in which we are invested and continue to search for new ideas and investment opportunities.

Sincerely,



Alex Umansky
Portfolio Manager

Investors should consider the investment objectives, risks, and charges and expenses of the investment carefully before investing. The prospectus and summary prospectus contains this and other information about the Funds. You may obtain them from its distributor, Baron Capital, Inc., by calling 1-800-99BARON or visiting www.BaronFunds.com. Please read them carefully before investing.

Risks: Growth stocks can react differently to issuer, political, market and economic developments than the market as a whole. Non-U.S. investments may involve additional risks to those inherent in U.S. investments, including exchange-rate fluctuations, political or economic instability, the imposition of exchange controls, expropriation, limited disclosure and illiquid markets, resulting in greater share price volatility. Securities of small and medium-sized companies may be thinly traded and more difficult to sell. The Fund may not achieve its objectives. Portfolio holdings are subject to change. Current and future portfolio holdings are subject to risk.

The discussions of the companies herein are not intended as advice to any person regarding the advisability of investing in any particular security. The views expressed in this report reflect those of the respective portfolio managers only through the end of the period stated in this report. The portfolio manager's views are not intended as recommendations or investment advice to any person reading this report and are subject to change at any time based on market and other conditions and Baron has no obligation to update them.

This report does not constitute an offer to sell or a solicitation of any offer to buy securities of Baron Global Advantage Fund by anyone in any jurisdiction where it would be unlawful under the laws of that jurisdiction to make such offer or solicitation.